PreveCeutical Medical Inc (18H) - Total Assets
Based on the latest financial reports, PreveCeutical Medical Inc (18H) holds total assets worth €456.04K EUR (≈ $533.16K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PreveCeutical Medical Inc - Total Assets Trend (2016–2024)
This chart illustrates how PreveCeutical Medical Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of PreveCeutical Medical Inc for the company's overall valuation and market capitalisation.
PreveCeutical Medical Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
PreveCeutical Medical Inc's total assets of €456.04K consist of 51.9% current assets and 48.1% non-current assets. Review debt load of PreveCeutical Medical Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 26.2% |
| Accounts Receivable | €27.19K | 12.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €106.44K | 47.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how PreveCeutical Medical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PreveCeutical Medical Inc (18H) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PreveCeutical Medical Inc's current assets represent 51.9% of total assets in 2024, a decrease from 98.7% in 2016.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2024, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 47.2% of total assets.
PreveCeutical Medical Inc Competitors by Total Assets
Key competitors of PreveCeutical Medical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
PreveCeutical Medical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.05 | 0.13 |
| Quick Ratio | 0.04 | 0.05 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-7.49 Million | €-6.34 Million | €-1.77 Million |
PreveCeutical Medical Inc - Advanced Valuation Insights
This section examines the relationship between PreveCeutical Medical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 14.78 |
| Asset Growth Rate (YoY) | 24.3% |
| Total Assets | €225.66K |
| Market Capitalization | $3.34 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PreveCeutical Medical Inc's assets at a significant premium (14.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: PreveCeutical Medical Inc's assets grew by 24.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PreveCeutical Medical Inc (2016–2024)
The table below shows the annual total assets of PreveCeutical Medical Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €225.66K ≈ $263.82K |
+24.32% |
| 2023-12-31 | €181.51K ≈ $212.20K |
-4.03% |
| 2022-12-31 | €189.14K ≈ $221.12K |
+17.33% |
| 2021-12-31 | €161.20K ≈ $188.46K |
-46.70% |
| 2020-12-31 | €302.45K ≈ $353.60K |
-64.73% |
| 2019-12-31 | €857.64K ≈ $1.00 Million |
-54.91% |
| 2018-12-31 | €1.90 Million ≈ $2.22 Million |
-26.83% |
| 2017-12-31 | €2.60 Million ≈ $3.04 Million |
+1154.77% |
| 2016-12-31 | €207.18K ≈ $242.22K |
-- |
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disor… Read more